Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Weng MC1, Li MH2, Chung JG3, Liu YC4, Wu JY5, Hsu FT6, Wang HE7. Biomed Pharmacother. 2019 Aug;116:109032. doi: 10.1016/j.biopha.2019.109032. Epub 2019 Jun 1.

Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Baity M1, Wang L2, Correa AM2, et al. Am J Cancer Res. 2019 Jun 1;9(6):1201-1211. eCollection 2019.

Interleukin-17 Promotes Migration and Invasion of Human Cancer Cells Through Upregulation of MTA1 Expression. Guo N1,2, Shen G1, Zhang Y3, Moustafa AA1, Ge D1, You Z1,4,5,6,7,8. Front Oncol. 2019 Jun 20;9:546. doi: 10.3389/fonc.2019.00546. eCollection 2019.

Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. Zhao H1, Wang Y2, Ren X3. Biosci Rep. 2019 Jun 7;39(6). pii: BSR20182443. doi: 10.1042/BSR20182443. Print 2019 Jun 28.

Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review. Swaminath A1, Vella ET2, Ramchandar K3, Robinson A4, Simone C5, Sun A6, Ung YC7, Yasufuku K8, Ellis PM9. Curr Oncol. 2019 Jun;26(3):e398-e404. doi: 10.3747/co.26.4549. Epub 2019 Jun 1.

Small Lung Tumor Biopsy Samples Are Feasible for High Quality Targeted Next Generation Sequencing. Kage H1, Kohsaka S2, Shinozaki-Ushiku A3, et al. Cancer Sci. 2019 Jun 21. doi: 10.1111/cas.14112. [Epub ahead of print]

Accuracy of Canine Scent Detection of Non-Small Cell Lung Cancer in Blood Serum. Junqueira H, Quinn TA, Biringer R, Hussein M, Smeriglio C, Barrueto L, Finizio J, Huang XYM. J Am Osteopath Assoc. 2019 Jun 17. doi: 10.7556/jaoa.2019.077. [Epub ahead of print]

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. Luo YH1, Luo L2, Wampfler JA3, Wang Y4, Liu D5, Chen YM6, Adjei AA7, Midthun DE8, Yang P9. Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30329-8. doi: 10.1016/S1470-2045(19)30329-8. [Epub ahead of print]

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. Park CK1,2, Kim JE1,2, Kim MS1,2, et al. J Cancer Res Clin Oncol. 2019 Jun 1. doi: 10.1007/s00432-019-02944-w. [Epub ahead of print]

Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma. Pagan C1, Barua S1, Hsiao SJ1, Mansukhani M1, Saqi A1, Murty V1, Fernandes H1. Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). pii: a003939. doi: 10.1101/mcs.a003939. Print 2019 Jun.

Assessment of non-lobe-specific lymph node metastasis in clinical stage IA non-small cell lung cancer. Zhang Z1, Miao J1, Chen Q1, Fu Y1, Li H1, Hu B1. Thorac Cancer. 2019 Jul;10(7):1597-1604. doi: 10.1111/1759-7714.13121. Epub 2019 Jun 17.

Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis. Spencer KL1,2,3, Kennedy MPT1,3, Lummis KL4, Ellames DAB1, Snee M1, Brunelli A1, Franks K1, Callister MEJ1. Eur Respir J. 2019 Jun 20;53(6). pii: 1801568. doi: 10.1183/13993003.01568-2018. Print 2019 Jun.

Postoperative Recurrence and Survival After Segmentectomy for Clinical Stage 0 or IA Lung Cancer. Kamigaichi A1, Tsutani Y1, Fujiwara M1, Mimae T1, Miyata Y1, Okada M2. Clin Lung Cancer. 2019 Jun 13. pii: S1525-7304(19)30146-9. doi: 10.1016/j.cllc.2019.06.004. [Epub ahead of print]

Effect of insurance type on perioperative outcomes after robotic-assisted pulmonary lobectomy for lung cancer. Deol PS1, Sipko J1, Kumar A2, Tsalatsanis A2, Moodie CC3, Garrett JR3, Fontaine JP4,

Salvage treatment with anlotinib for advanced non-small cell lung cancer. Wu D1, Nie J1, Dai L1, et al. Thorac Cancer. 2019 Jul;10(7):1590-1596. doi: 10.1111/1759-7714.13120. Epub 2019 Jun 10.

Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Rahouma M1, Karim NA2, Baudo M3, et al. Immunotherapy. 2019 Jun;11(8):725-735. doi: 10.2217/imt-2018-0118.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Reck M1, Schenker M2, Lee KH3, et al. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.

Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Fujimoto D1, Yomota M2, Sekine A3, Morita M4, Morimoto T5, Hosomi Y2, Ogura T3, Tomioka H4, Tomii K6. Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494-5. doi: 10.1016/j.lungcan.2019.06.001. [Epub ahead of print]

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Lau SCM1, Batra U2, Mok TSK3,4, Loong HH5,6,7. Drugs. 2019 Jun;79(8):823-831. doi: 10.1007/s40265-019-01115-y.

PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Rossi A1, Noia VD2, Gkountakos A3, et al. Immunotherapy. 2019 Jul;11(10):921-930. doi: 10.2217/imt-2018-0198. Epub 2019 Jun 3.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Garon EB1, Hellmann MD2, Rizvi NA3, et al. J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934. [Epub ahead of print]

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Mu Y1, Hao X1, Yang K2, Ma D1, Wang S1, Xu Z1, Li J3, Xing P4. Target Oncol. 2019 Jun;14(3):335-342. doi: 10.1007/s11523-019-00644-6.

Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer. Levy BP1, Signorovitch JE2, Yang H2, Patterson-Lomba O2, Xiang CQ2, Parisi M3. Curr Oncol. 2019 Jun;26(3):e300-e308. doi: 10.3747/co.26.4485. Epub 2019 Jun 1.

Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Lacour M1, Hiltbrunner S2, Lee SY2, Soltermann A3, Rushing EJ4, Soldini D3, Weder W1, Curioni-Fontecedro A5. Clin Lung Cancer. 2019 Jun 5. pii: S1525-7304(19)30140-8. doi: 10.1016/j.cllc.2019.05.013. [Epub ahead of print]

Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Lacour M1, Hiltbrunner S2, Lee SY2, Soltermann A3, Rushing EJ4, Soldini D3, Weder W1, Curioni-Fontecedro A5. Clin Lung Cancer. 2019 Jun 5. pii: S1525-7304(19)30140-8. doi: 10.1016/j.cllc.2019.05.013. [Epub ahead of print]

Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases. Lee CC1,2,3, Hsu SPC1,2, et al. J Neurosurg. 2019 Jun 21:1-8. doi: 10.3171/2019.4.JNS19446. [Epub ahead of print]

Timing of adjuvant radiation therapy and survival outcomes after surgical resection of intracranial non-small cell lung cancer metastases. Sheppard JP1, Prashant GN1, Chen CHJ1, et al. Clin Neurol Neurosurg. 2019 Jun 15;183:105389. doi: 10.1016/j.clineuro.2019.105389. [Epub ahead of print]

Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy. Rice SR1, Saboury B2, Houshmand S2, et al. Nucl Med Commun. 2019 Jun;40(6):618-625. doi: 10.1097/MNM.0000000000000997.

Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer. Takahashi S1, Go T2, Anada M3, Kinoshita T3, Nishide T3, Yokomise H2, Shibata T3. Anticancer Res. 2019 Jun;39(6):2957-2962. doi: 10.21873/anticanres.13426.

A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. Munoz-Schuffenegger P1, Kandel S2, Alibhai Z3, Hope A1, Bezjak A1, Sun A1, Simeonov A1, Cho BCJ1, Giuliani M4. Clin Oncol (R Coll Radiol). 2019 Jun 5. pii: S0936-6555(19)30206-7. doi: 10.1016/j.clon.2019.05.014. [Epub ahead of print]

Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis. Donovan EK1, Parpia S2, Greenspoon JN1. Curr Oncol. 2019 Jun;26(3):e328-e333. doi: 10.3747/co.26.4749. Epub 2019 Jun 1.

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer. Dubaere E1, Goffaux M2, Wanet M1, et al. BMC Cancer. 2019 Jun 28;19(1):639. doi: 10.1186/s12885-019-5863-2.

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. Atkins KM1, Rawal B2, Chaunzwa TL3, et al. J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987. doi: 10.1016/j.jacc.2019.03.500.

Role of prophylactic cranial irradiation for elderly patients with limited-disease small-cell lung cancer: inverse probability of treatment weighting using propensity score. Kim TG1, Pyo H2, Ahn YC2, Noh JM2, Oh D2. J Radiat Res. 2019 Jun 5. pii: rrz040. doi: 10.1093/jrr/rrz040. [Epub ahead of print]

Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes. Iams WT1, Shiuan E2, Meador CB2, et al. J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463-0. doi: 10.1016/j.jtho.2019.05.042. [Epub ahead of print]

PET Imaging of a [18F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts. Laird J1, Lok BH2, Carney B3, Kossatz S4, de Stanchina E5, Reiner T6, Poirier JT7, Rudin CM8. J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453-8. doi: 10.1016/j.jtho.2019.05.032. [Epub ahead of print]

Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Sun A1, Durocher-Allen LD2, Ellis PM3,4, Ung YC5, Goffin JR3, Ramchandar K6, Darling G7. Curr Oncol. 2019 Jun;26(3):e372-e384. doi: 10.3747/co.26.4481. Epub 2019 Jun 1.

MYC-driven small cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Chalishazar MD1, Wait SJ2, Huang F3, et al. Clin Cancer Res. 2019 Jun 4. pii: clincanres.4140.2018. doi: 10.1158/1078-0432.CCR-18-4140. [Epub ahead of print]

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Tian Y1, Zhai X2,3, Han A3, Zhu H4,5, Yu J6,7. J Hematol Oncol. 2019 Jun 28;12(1):67. doi: 10.1186/s13045-019-0753-2.

Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Hu J1,2, Wang Y3, Zhang Y4, Yu Y4, Chen H4, Liu K4, Yao M4, Wang K4,5, Gu W6,7, Shou T1,2. Cancer Med. 2019 Jun 14. doi: 10.1002/cam4.2199. [Epub ahead of print]

Dispositional mindfulness, self-compassion, and compassion from others as moderators between stress and depression in caregivers of patients with lung cancer. Hsieh CC1, Yu CJ2, Chen HJ3, Chen YW4, Chang NT1, Hsiao FH1,5. Psychooncology. 2019 Jul;28(7):1498-1505. doi: 10.1002/pon.5106. Epub 2019 Jun 6.

Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cavalheri V1, Burtin C, Formico VR, Nonoyama ML, Jenkins S, Spruit MA, Hill K. Cochrane Database Syst Rev. 2019 Jun 17;6:CD009955. doi: 10.1002/14651858.CD009955.pub3.

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Ricciuti B1, Dahlberg SE1, Adeni A1, Sholl LM2, Nishino M2, Awad MM1. J Clin Oncol. 2019 Jun 17:JCO1900189. doi: 10.1200/JCO.19.00189. [Epub ahead of print]

Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients. Steffen LE1, Cheavens JS2, Vowles KE3, Gabbard J4, Nguyen H5, Gan GN6, Edelman MJ7, Smith BW3. Support Care Cancer. 2019 Jun 1. doi: 10.1007/s00520-019-04878-y. [Epub ahead of print]

Manifestations of anxiety and coping strategies in patients with metastatic lung cancer and their family caregivers: a qualitative study. Hendriksen E1, Rivera A2, Williams E2, Lee E2, Sporn N3, Cases MG1, Palesh O1. Psychol Health. 2019 Jul;34(7):886-899. doi: 10.1080/08870446.2019.1579909. Epub 2019 Jun 3.

Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized Trial. Mosher CE1, Secinti E2, Hirsh AT2, Hanna N3, Einhorn LH3, Jalal SI4, Durm G3, Champion VL5, Johns SA6. J Pain Symptom Manage. 2019 Jun 27. pii: S0885-3924(19)30365-3. doi: 10.1016/j.jpainsymman.2019.06.021. [Epub ahead of print]

Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer. Zhang J1, Zhang Y1, Shen W1, Fu R1, Ding Z1, Zhen Y2, Wan Y3. Biomed Pharmacother. 2019 Jun 5;117:109058. doi: 10.1016/j.biopha.2019.109058. [Epub ahead of print]

Yi-qi-yang-yin-tian-sui-fang enhances cisplatin-induced tumor eradication and inhibits interleukin-7 reduction in non-small cell lung cancer. Ke B1, Wu X1, Yang Q2, Huang Y3, Wang F4, Gong Y5, Liu J5, Shi L6. Biosci Rep. 2019 Jun 28;39(6). pii: BSR20190052. doi: 10.1042/BSR20190052. Print 2019 Jun 28.

Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. Barger S1, Sullivan SD2, Bell-Brown A1, et al. BMC Med Res Methodol. 2019 Jun 11;19(1):119. doi: 10.1186/s12874-019-0764-2.

Smoking and Smoking Cessation Among Persons with Tobacco- and Non-tobacco-Associated Cancers. Gallaway MS1, Huang B2,3, Chen Q3, Tucker TC3,4, McDowell JK3, Durbin E3,5, Stewart SL6, Tai E6. J Community Health. 2019 Jun;44(3):552-560. doi: 10.1007/s10900-019-00622-z.

Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. Shepshelovich D1, Xu W2, Lu L3, et al. J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30416-2. doi: 10.1016/j.jtho.2019.05.031. [Epub ahead of print]

Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. Ludmir EB1, Mainwaring W2, Lin TA1,2, et al. JAMA Oncol. 2019 Jun 3. doi: 10.1001/jamaoncol.2019.2055. [Epub ahead of print]

Comparison of Hospitals Affiliated With PPS-Exempt Cancer Centers, Other Hospitals Affiliated With NCI-Designated Cancer Centers, and Other Hospitals That Provide Cancer Care. Merkow RP1,2, Yang AD1,2, Pavey E1, Song MW3, Chung JW1,2, Bentrem DJ1,2,4, Bilimoria KY1,2. JAMA Intern Med. 2019 Jun 17. doi: 10.1001/jamainternmed.2019.0914. [Epub ahead of print]

County-level radon exposure and all-cause mortality risk among Medicare beneficiaries. Yitshak-Sade M1, Blomberg AJ2, Zanobetti A2, Schwartz JD3, Coull BA4, Kloog I5, Dominici F4, Koutrakis P2. Environ Int. 2019 Jun 11;130:104865. doi: 10.1016/j.envint.2019.05.059. [Epub ahead of print]